|
|
Volumn 5, Issue 4, 1996, Pages 429-445
|
|
Drugs in development for the treatment of metabolic bone disease
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2BETA (3 HYDROXYPROPOXY)CALCITRIOL;
ALENDRONIC ACID;
BISPHOSPHONIC ACID DERIVATIVE;
CALCITONIN;
CALCITRIOL;
CLODRONIC ACID;
DROLOXIFENE;
EF 40;
ESTROGEN;
ETIDRONIC ACID;
FALECALCITRIOL;
IBANDRONIC ACID;
IDOXIFENE;
IPRIFLAVONE;
NORCALCIN;
PAMIDRONIC ACID;
RALOXIFENE;
RISEDRONIC ACID;
SC 116;
SECALCIFEROL;
STRONTIUM;
STRONTIUM RANELATE;
TAMOXIFEN;
TAMOXIFEN DERIVATIVE;
TIBOLONE;
TILUDRONIC ACID;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VITAMIN D DERIVATIVE;
ANIMAL MODEL;
BONE DEVELOPMENT;
BREAST CANCER;
CANCER;
CLINICAL TRIAL;
DRUG INDICATION;
HUMAN;
HYPERCALCEMIA;
METABOLIC BONE DISEASE;
NONHUMAN;
OSTEOLYSIS;
OSTEOPOROSIS;
PAGET BONE DISEASE;
POSTMENOPAUSE OSTEOPOROSIS;
REVIEW;
|
|
EID: 0029912224
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.5.4.429 Document Type: Review |
|
Times cited : (5)
|
|
References (0)
|
